Angular Tricyclic Compounds for G9a GLP Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and hemoglobinopathies, such as beta-thalassemia and sickle cell disease, lack effective inhibitors for G9a and GLP histone methyltransferases, which are crucial for histone methylation and play significant roles in these diseases.
Innovation Solution
Development of specific angular tricyclic compounds that act as G9a and/or GLP inhibitors, formulated into pharmaceutical compositions for therapeutic use, targeting the G9a-GLP complex to modulate histone methylation and gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancers and hemoglobinopathies are used, then existing therapeutic options are maintained, but effective inhibition of G9a and GLP histone methyltransferases is not achieved
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure of angular tricyclic compounds to achieve effective G9a and GLP inhibition. The compounds feature specific structural parameters including an angular tricyclic core with particular substituent patterns that enable selective binding to the methyltransferase active site, thereby improving therapeutic efficacy through precise parameter optimization rather than using existing treatments
Solution Approach 2:
The angular tricyclic compounds act as intermediary molecules that mediate between the therapeutic goal and the biological target. These compounds serve as small molecule intermediaries that specifically bind to G9a and GLP enzymes, blocking their methyltransferase activity and thereby transmitting the therapeutic effect without requiring direct genetic manipulation or using existing ineffective treatments
2Object-affected harmful factors
If G9a and GLP activity is inhibited, then tumor growth and metastasis are suppressed, but the complexity of developing specific inhibitors increases
Solution Approach 1:
The inhibitor development process is segmented into manageable components through the angular tricyclic molecular architecture. The compound structure is divided into distinct functional segments: the angular tricyclic core that provides structural rigidity and binding geometry, and specific substituent groups that interact with key residues in the G9a/GLP active site. This segmentation allows for systematic optimization of each component to achieve effective inhibition while managing development complexity
Solution Approach 2:
The patent applies local quality by designing substituents with specific properties at particular positions on the angular tricyclic core. Different substituent types (electron-withdrawing, electron-donating, hydrophobic, hydrophilic) are placed at specific locations to optimize interactions with different regions of the enzyme binding pocket, thereby achieving effective tumor growth suppression through localized structural optimization rather than uniform molecular design
3Object-affected harmful factors
If G9a and GLP are inhibited to increase fetal hemoglobin production, then hemoglobinopathies are treated, but the need for novel compound development increases complexity
Solution Approach 1:
The angular tricyclic compounds exhibit universality by serving multiple therapeutic functions: they inhibit both G9a and GLP enzymes simultaneously, they can treat different hemoglobinopathies (beta-thalassemia, sickle cell disease), and they may have potential applicability to other diseases involving histone methylation dysregulation. This multi-functionality is achieved through the compounds' ability to bind to a conserved region of both enzymes, simplifying the therapeutic approach compared to developing separate inhibitors for each condition
Solution Approach 2:
The patent employs copying by creating synthetic analogs of natural product structures that mimic the binding mode of known inhibitors. The angular tricyclic core resembles structural features of naturally occurring compounds that interact with epigenetic enzymes, allowing the use of established synthetic methodologies from natural product chemistry to manufacture the inhibitors, thereby improving ease of manufacture through leveraging existing synthetic knowledge and techniques
Data Source
AI summary
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., betathalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.